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The Pipeline Endovascular Device versus the Flow Re-Direction Endoluminal
Device for Cerebral Aneurysm. A One-Year Follow-up in a Single-Center
Experience
Abstract
Background: The Flow Diverters are devices derived from brain stents, made up of a network of
microfilaments of various materials that allow the vessel remodeling. The Pipeline Embolization Device
and The Flow Re-Direction Endoluminal Device are the two devices with more global clinical experience.
Our objective is to compare the 1-year results using these devices in a cohort of patients assessing their
occlusion rate and their clinical outcome as by the modified Rankin Score (mRS).
Methods: In this retrospective nested case-control cohort study, we reviewed the medical records of
patients undergoing treatment with a Flow Diverter stent for brain aneurysms with a 1-year follow up. We
considered the following inclusion criteria: patients between 18 and 80 years of age, with at least one
cerebral aneurysm and aneurysms in the segments of the internal carotid artery and vertebral arteries. We
recorded the clinical presentation as subarachnoid hemorrhage, headache, mass effect, transient
ischemic attack, family history, and incidentals. Demographic data, topography, quantity, and lateralization
of all aneurysms were collected.
Results: A total of 91 patients were included in the final analysis. The 6-month occlusion rate was 91.5%
for PED and 95.7% for FRED 95.7% (p 0.597); and at 12 months it was 95.7% for PED and 97.7 for FRED (p
0.555). In pairing the propensity score (PPS) the complete occlusion rate was 90% for PED and 100% for
FRED, without statistical significance in the difference at 12 months (p 0.631).
Conclusion: Flow diversion devices PED and FRED are an efficient treatment for aneurysms of the anterior
circulation and some of the posterior circulation (vertebral arteries), showing similar occlusion rates and
clinical outcomes.
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Abstract
Background: The Flow Diverters are devices derived from brain stents, made up of a network of microﬁlaments of
various materials that allow the vessel remodeling. The Pipeline Embolization Device and The Flow Re-Direction
Endoluminal Device are the two devices with more global clinical experience. Our objective is to compare the 1-year
results using these devices in a cohort of patients assessing their occlusion rate and their clinical outcome as by the
modiﬁed Rankin Score (mRS).
Methods: In this retrospective nested case-control cohort study, we reviewed the medical records of patients undergoing treatment with a Flow Diverter stent for brain aneurysms with a 1-year follow up. We considered the following
inclusion criteria: patients between 18 and 80 years of age, with at least one cerebral aneurysm and aneurysms in the
segments of the internal carotid artery and vertebral arteries. We recorded the clinical presentation as subarachnoid
hemorrhage, headache, mass effect, transient ischemic attack, family history, and incidentals. Demographic data,
topography, quantity, and lateralization of all aneurysms were collected.
Results: A total of 91 patients were included in the ﬁnal analysis. The 6-month occlusion rate was 91.5% for PED and
95.7% for FRED 95.7% (p 0.597); and at 12 months it was 95.7% for PED and 97.7 for FRED (p 0.555). In pairing the
propensity score (PPS) the complete occlusion rate was 90% for PED and 100% for FRED, without statistical signiﬁcance
in the difference at 12 months (p 0.631).
Conclusion: Flow diversion devices PED and FRED are an efﬁcient treatment for aneurysms of the anterior circulation
and some of the posterior circulation (vertebral arteries), showing similar occlusion rates and clinical outcomes.
Keywords: Aneurysm, Occlusion rate, Flow diverter, PED, FRED, Embolization

1. Background

C

erebral aneurysms surgery has been one of
the most challenging procedures since the
beginning of modern neurosurgery. The incorporation of the surgical microscope - by Theodore

Kurze in 1957 - and the subsequent development
of microsurgical techniques (by outstanding exponents such as M.G. Yasargil) made great strides
in the neurovascular ﬁelds [1]. Simultaneously,
medical devices achieved a signiﬁcant leap forward in blood vessel navigation to solve cerebral
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aneurysms by creating a system that allowed the
introduction of platinum coils into the aneurysm
dome sufﬁciently safe to be even released by
electrolysis [2]. G. Gugliemi's publication about
the use of these new coils reported morbidity and
mortality as low (for cerebral aneurysms) as 4.8
and 2.4%, respectively [3]. With proper time and
effort, neuroendovascular techniques gained an
essential role in the cerebrovascular diseases'
armamentarium by their results, which ended up
currently, in the design of Flow Diverters [4].
Flow Diverters (FDs) are devices derived from
brain stents that take advantage of the principle of
vascular remodeling to reconstruct the parent vessel
carrying the aneurysm. A network of distinct microﬁlaments constitutes the structure of a Flow
Diverter that enables the creation of a new arterial
wall by interrupting the blood ﬂow within the
aneurysmal sac, permitting vessel remodeling over
the stent's full length [5].
The PipelineTM Embolization Device (PED,
Medtronic, Dublin, Ireland) consists of a braided
mesh ﬂexible tube of 48 interwoven microﬁlaments,
25% platinum-tungsten, and 75% cobalt-chromiumnickel alloy [6]. In 2008 Nelson P. reported the use of
the Pipeline device for the ﬁrst time.; later published
in the PITA trial in 2011. This device consisted of 48
individual cobalt chrome microﬁlaments in their
initial version [7]. In 2009, Lylyk P. et al. reported its
use in 53 patients, concluding that PED reconstruction was durable, safe, and curative [8].
The Flow Re-Direction Endoluminal Device
(FREDTM; MicroVention, Tustin, California) is a
self-expanding nickel-titanium paired stent. It
comprises an integrated dual-layer coverage provided by a low-porosity inner mesh of higher pore
attenuation (48 nitinol wires) and an outer stent with
high porosity (16 nitinol wires with four interwoven
marker strands), that has proximal and distal
markers [9]. The global clinical experience with this
device is minor than that of PED, provided that the
FDA approval process started after 2018; therefore,
it developed mainly in Europe [10].
This report compares the results of patients
implanted with these devices, assessing their occlusion rate and their clinical outcomes (mRS) at 1year follow-up.

2. Methods
In this nested caseecontrol retrospective cohort
study, we reviewed the medical records of patients
undergoing treatment with a Flow Diverter stent for
cerebral aneurysms within a Mexican hospital at
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Abbreviation list
AVA
Advanced Vessel Analysis
COFEPRIS
Federal Commission for the Protection
Against Health Risks (name in Spanish)
DSA
Digital subtraction angiography
FD
Flow Diverter
FDA
Food and Drug Administration
FRED
Flow Redirection Endoluminal Device
PED
Pipeline Embolization Device version Flex
PITA
The pipeline embolization device for the intracranial treatment of aneurysms trial
PPS
Pairing propensity score
mRS
Modify Rankin Score
SPSS
Statistical Package for the Social Sciences

one year-follow-up. The selection began in October
2016 and ended in December 2019; all cases had at
least one control, Digital Subtraction Angiography
(DSA), by December 2019. We included patients
between 18 and 85 years of age, at least one cerebral
aneurysm, aneurysm located in segments of the
internal carotid artery and vertebral arteries
regardless of lateralization. Pediatric patients, aneurysms located at the middle cerebral artery
bifurcation, anterior communicating artery, basilar
artery, and distal arteries less than 2.75 mm, and
those with combined use of devices were excluded.
We recorded clinical presentation as follows: subarachnoid hemorrhage, headache, mass effect,
transient ischemic attack, family history, and incidentals. Demographic data, topography, quantity,
and lateralization of all aneurysms were collected.
All procedures were done under general anesthesia with one of the two FDs available at our
center: the Pipeline Embolization Device version
Flex (PED) or the Flow Redirection Endoluminal
Device (FRED). We did not consider the use of
additional coils for the analysis, mainly because our
resources were often limited, impeding the use of
assisted coils with ﬂow diverter, even though it was
a reasonable option. The selection of the FD
depended exclusively on the treating physician; the
patients signed informed consent before the procedure in every case. All the patients received dual
antiplatelet therapy for seven days before the procedure with 100 mg aspirin and 75 mg clopidogrel
daily. If any patient was unable to complete this
protocol for any reason, we administered a short
scheme consisting of 100 mg aspirin and a clopidogrel loading dose of 150 mg every 2hrs until
reaching a total 450 mg at least 12hrs before the
procedure. We used the VerifyNowTM device
(Accumetrics, Bedford, MA, USA) in all the patients
to verify the antiplatelet effect. We used clopidogrel
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for six months and acetylsalicylic acid for at least
one year after the procedure in every case. The
procedures were performed through a puncture in
the right or left common femoral artery, using a 6 Fr
access system as a standard; however, an 8 Fr was
used in some cases. A 5000 IU bolus of heparin was
administered at the beginning of the catheter's
intracranial access, followed by hourly bolus doses
of 1000 IU to maintain activated clotting time between 2 and 2.5 times the basal value. In no case,
more than 7500 IU were used in total.
In all the cases, the Angio-SealTM (Terumo Corporation, Tokyo, Japan) vascular closure device was
used. The complete deployment of the device used,
its permeability and apposition in the parent vessel,
and the aneurysm sac contrast retention was
reviewed at the end of the procedure. In some cases,
the ﬁrst follow-up was performed at three months,
based on speciﬁc circumstances; however, for the
data analysis, the ﬁrst follow-up was considered at
six months and the last one at 12 months. Standard
angiographic projections were used in addition to
other projections used as required during treatment. Aneurysm occlusion was graded using the
RaymondeRoy (CRR) classiﬁcation [11], and the
functional result was evaluated using the modiﬁed
Rankin Scale (mRS) at 90 days and on each followup (6 and 12 months) by complete neurological examination. Standard techniques were used to measure the height and width of the aneurysm dome
and the width of the aneurysmal neck. The
Advanced Vessel Analysis (AVA®) software (Philips, Best, The Netherlands) was used to calculate
the length of the affected artery and the length between the proximal and distal edge of the aneurysm.
2.1. Statistical analysis
We used standard techniques to measure the
height and width of the aneurysm dome and the
width of the aneurysmal neck. Even more, we used
the Advanced Vessel Analysis (AVA®) software
(Philips, Best, The Netherlands) to calculate the
length of the affected artery and the length between
the proximal and distal edge of the aneurysm. We
collected and coded data related to the patients'
proﬁle, the aneurysm characteristics, and the device
used in every procedure as appropriate. We divided
the patient's sample into two groups based on the
implanted device for the analysis. We reported
categorical variables as proportions and continuous
variables as means, standard deviations, or median
interquartile-ranges as appropriate according to the
data's distribution. We compared categorical variables using the chi-square test in each group,
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whereas
continuous
variables
with
the
ManneWhitney U test. Additionally, we performed
a sub-analysis based on the propensity score
matching for age, sex, aneurysm size, and location.
We performed these statistical analyses using IBM's
Statistical Package for the Social Sciences (SPSS
Statistics®) Version 23.

3. Results
Data were collected from 96 patients; two were
excluded because of being pediatric patients (5 and
12 years old), one by having a basilar aneurysm, an
additional one by losing follow-up at six months,
and one more derived from the combined use of
devices (telescoped). A total of 91 patients were
analyzed, 41 (45.1%) were men and 50 (54.9%)
women. The average age of the patients was 61
Table 1. Global baseline data.
Gender
Male
Female
Age
Num. Aneurysms
Size. Aneurysms
Clinical Presentation
Incidental
Headache
Family History
SAH
Mass Effect
TIA
Parent Vessel Localization
pComA
Ophthalmic/para-ophthalmic
Cavernous
Ant. Choroidal
Hypohyseal
Petrous
Vertebral
Posterior Cerebral Artery
Middle Cerebral Artery
Side
Left
Right
Device
PED
FRED
Occlusion (12 months)
Complications
Neurological
Non-neurological
mRS
0
1
2
6

n
41
50
61 (þ10.7)
127
11 (þ5)

%
45.1
54.9

38
37
8
5
2
1

41.8
40.7
8.8
5.5
2.2
1.1

28
18
15
9
8
6
5
1
1

30.8
19.8
16.5
9.9
8.8
6.6
5.5
1.1
1.1

48
43

52.7
47.3

47
44
83

51.6
48.4
91.2

4
6

4.4
6.6

87
1
2
1

95.6
1.1
2.2
1.1

PED: Pipeline Embolization Device; FRED: Flow Re-Direction
Endoluminal Device.
SAH, subarachnoid hemorrhage; mRS: modiﬁed Rankin scale.
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years (range 18e85 years). The most frequent clinical presentation was the category of incidental aneurysms (n ¼ 38, 41.8%), followed by the patients
who presented headache (n ¼ 37, 40.7%), the rest
were divided between SAH (subarachnoid hemorrhage), mass effect, TIA (transient ischemic attack)
and, family history (Table 1). A total of 127 (mean
1.2) aneurysms were found, most of them were
found on the right side (n ¼ 48, 52.7%), the rest on
the left side. The most frequent locations were
pComA (n ¼ 28, 30.8%), ophthalmic/paraophthalmic (n ¼ 18, 19.8%) and cavernous (n ¼ 15,
16.5%). The mean major axis of the aneurysms was
11.6 mm (þ5); 45 aneurysms were <10 mm (52.7%)
were found; 43 (47.3%) > 10 but <25 mm and 3
(3.3%) >25 mm. The Pipeline device (PED) was used
in 48 (52.7%) cases and FRED in 43 (47.3%). A total of
10 cases had complications; six were minor and nonneurological such as epistaxis, minor local
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hematoma, or groin pain. Three neurological complications (3.3%) occurred in the FRED group,
including two events of thromboembolism (2.2%)
and one intra-stent thrombosis (1.1%); two of those
patients had an mRS of 2 at 90 days completely
improving at 12 months. One death occurred in the
PED group occurred, while none in the FRED group
(Table 2). The 6-month occlusion rate was 91.5% for
PED and 95.7% for FRED 95.7% (p 0.597); and at 12
months it was 95.7% for PED and 97.7 for FRED (p
0.555).
In pairing the propensity score (PPS) controlling
for age, sex, and size and location of the aneurysms,
20 aneurysms were obtained, 10 for each group.
With PPS, the complete occlusion rate was 90% for
PED and 100% for FRED, without statistical signiﬁcance in the difference at 12 months (p 0.631). The
functional result and complications were not
different (Table 3).

Table 2. Comparison between PED and FRED patients.
PED ¼ 47
Gender
Male
Female
Age
Num. Aneurysms
Size. Aneurysms
Clinical Presentation
Incidental
Headache
Family History
SAH
Mass Effect
TIA
Parent Vessel Localization
pComA
Ophthalmic/para-ophthalmic
Cavernous
Ant. Choroidal
Hypohyseal
Petrous
Vertebral
Posterior Cerebral Artery
Middle Cerebral Artery
Side
Left
Right
Occlusion (6 months)
Occlusion (12 months)
Complications
Neurological
Non-neurological
mRS (90 days)
0
1
2
6

FRED ¼ 43

n
21
26
61 (11)
65
10 (4.8)

%
44.7
55.3

17
20
3
5
1
1

p

n
20
24
61 (10.6)
59
11 (5.4)

%
45.5
54.5

36.2
42.6
6.4
10.6
2.1
2.1

21
17
5
0
1
0

47.7
38.6
11.4
0.0
2.3
0.0

15
7
6
5
3
4
5
1
1

31.9
14.9
12.8
10.6
6.4
8.5
10.6
2.1
2.1

13
11
9
4
5
2
0
0
0

29.5
25.0
20.5
9.1
11.4
4.5
0.0
0.0
0.0

27
20
43
45

57.4
42.6
91.5
90.9

21
23
40
43

47.7
52.3
95.7
97.7

0.597
0.555

1
3

2.1
6.4

3
3

6.8
6.8

0.280
0.198

46
0
0
1

97.9
0.0
0.0
2.1

41
1
2

93.2
2.3
4.5

PED: Pipeline Embolization Device; FRED: Flow Re-Direction Endoluminal Device.
SAH, subarachnoid hemorrhage; mRS: modiﬁed Rankin scale.

0.942
0.842
0.438
0.005

0.086

0.353
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Table 3. Propensity score matching results.
Gender
Female
Age
Num. Aneurysms
Size. Aneurysms
Clinical Presentation
Incidental
Headache
Familiar History
Parent Vessel Localization
pComA
Ophthalmic/para-ophthalmic
Cavernous
Petrous
Side
Left
Right
Occlusion (12 months)
Complications
Neurological
Non-neurological
mRS (90 days)
0
1
2
6

PED ¼ 10

FRED ¼ 10

10
59 (8)
10
12 (3)

10
56 (11)
10
13 (3)

0.835

5
4
1

50
40
10

5
5
0

50
50
0

1
3
3
3

10
30
30
30

4
3
2
1

40
30
20
10

7
3
9

6
4
10

1

70
30
90
0
10

0

60
40
100
0
0

9
0
0
1

90
0
0
10

10
0
0
0

100
0
0
0

4. Discussion
This study was carried out in a single center in
northern Mexico City. During the data collection
and until the redaction of this paper, solely, these
two devices remain available at our center. The
Cofepris (Federal Commission for the Protection

Fig. 1. Flow Diverter prolapsed into the aneurysm. The arrow shows the
“watermelon seed effect”.

0.190
0.095

0.278

0.404
1
0.331
0.335

Against Health Risks) is the regulatory ofﬁce that
approves medical devices in Mexico. Until April
2020, the devices authorized for clinical use by this
authority include the PED, FRED, FRED JrTM,
Surpass StreamlineTM (Stryker Neurovascular,
Kalamazoo, Michigan), and Silk VistaTM (Balt
Extrusion, Montmorency, France). As by personal
communication with the authors, local providers
refer that authorization for intra-saccular and
various other ﬂow devices are in process. In our
country, the use of these devices began in 2014, with
isolated cases in different centers; in our hospital,
the ﬁrst FD implanted dates to December 2015.
Several authors reported occlusion rates close to
87.2% for FRED, with joint morbidity and mortality
rates of 4.1%; nevertheless, no 5-year follow-up reports exist to our knowledge [10,12,13]. Regarding
PED over ten years have passed since the device
began to be used, and several authors have reported
occlusion rates of 95.2% and combined morbidity
and mortality of 3.7% at ﬁve years follow-up
[14e16].
There are structural differences between these
two devices to assume or at least suspect that range
of occlusion and outcomes could be not similar. For
example, the FRED composition has a more rigid
and stable structure, with a pore density of <70%
and porosity of at least 20 pores/mm2 [17,18]. The
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PED has a 70% density; nevertheless, it has a predictable parabolic variability according to the parameters of the device, the size of the parent artery,
and the curvature of the device; for example, a
modest oversizing can increase porosity and
compromise the aneurysm occlusion [14,19].
Regarding the patient with outcome mRS of 6
(the patient's death in the PED group), the procedure was performed without complications, and
the patient was discharged 36hrs post-procedure.
The patient returned 48hrs after hospital discharge
due to sudden loss of consciousness and SAH
Fisher IV on Head CT. In a retrospective analysis,
we identiﬁed that the distal landing zone was too
short and was not enough to resist aneurysm
inﬂow; hence, the device did a “watermelon seed
effect,” causing a rupture and massive hemorrhage
[20] (Fig. 1).
The two distal thromboembolic complications in
the FRED group were resolved by direct thromboaspiration with the SoﬁaTM catheter (Microvention Inc., Aliso Viejo, CA), part of the triaxial
system for implantation. The intra-stent thrombosis
case in the FRED group was also managed by
aspiration, achieving recanalization in less than 10
min with a subsequent infusion of Tiroﬁban [21].
After Tiroﬁban's bolus, the team waited 30 min in
the angiosuit before taking off the endovascular
systems; no new clot was observed. Except for
epistaxis and slight hematuria, the patient had a
normal postoperative exam (NIHSS 0). Even though
he received the full dual anti-aggregation scheme,
demonstrated optimal PRU levels (200) in the pretreatment test (VerifyNow), he developed thrombosis, which has been reported to occur in this
scenario [22,23]. We do not change the anti-aggregation scheme because our health system does not
allow it; nevertheless, no additional problems
occurred.
The 12-month analysis by propensity score
matching indicated no signiﬁcant difference between both devices (PED 90% vs. FRED 100%),
although results are slightly in favor of FRED (p
0.550).
It is important to note that the mean aneurysmal
size for the entire cohort was 11 mm (±5 mm);
therefore, even when some cases were indeed large
or giant, most of the treated aneurysms were not,
which could favor a higher occlusion rate.
Our ﬁndings coincide with those reported by
Griessenauer et al. in their comparative study of
both devices [24]. Our results may have been limited
as a matter of insufﬁcient sample size, given that
differences among groups almost reached the preseated cutoff point (0.05) for statistical signiﬁcance,
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but even so still non-signiﬁcant; this is a matter of
future research.
The decision to choose one device over another
will probably depend on other factors (availability,
price, approval by local authorities, the experience
of the operator) and not exclusively on the clinical
outcomes. From our perspective, the parental vessel's tortuosity and the anatomical disposition of the
aneurysm are factors to consider when choosing one
of these two devices.

5. Conclusion
Flow diversion devices PED and FRED are efﬁcient means of treatment for aneurysms of the
anterior circulation and some of the posterior circulation (vertebral arteries), showing occlusion rates
and similar clinical outcomes between both of them.
Further studies are needed to determine if there are
substantial differences between these two devices
and others available around the world.
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Publication comment
In this publication, a single-center, single-surgeon
experience is provided using two endovascular devices widely available. Both of them are accepted by
the major health systems worldwide, having the FDA
and CE-Mark as well as the Mexican COFEPRIS
authorization. Each of these devices has pros and
cons, comparing their rigidity, self-expanding ability,
and delivery systems as well as the surgeon's preference. (1,2) Each case should be tailored to the patient considering the surgeon's ability to choose
between any of these devices and the other Flow
Diverters that are already approved and available in
different regions based on their proﬁles. In the
future, the decision will depend on deﬁning: Which
one has the earliest success rate of occlusion with the
longest follow-up and the least complications. Undoubtedly it has been tried to compare both devices
previously, even in multicenter studies (2), with a
similar mean follow-up. Due to the lack of long-term
follow-up in this comparison and the lack of prospective trials, every effort in this direction is to be
considered useful for decision-making. Provided that
these devices continue to show their efﬁcacy and
more Flow Diverters are available, the comparison
process of these devices will be more speciﬁc to each
type and location of the aneurysm. Therefore, this
experience should not be misleading or mistaken as
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a suggestion, to use one device over the other, since
in other trails and this publication itself shows there
are no statistical differences between the devices.
Christopher Mader Alba
Regional Hospital “Adolfo López Mateos”. Institute of
Security and Social Services of State Workers (ISSSTE)
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